Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11545932 | 0.92 | NPC1 (0.61) | NPC1RAB9ARECQLKMT2AMAPT | |
| SCHEMBL30967467 | 0.91 | NPC1 (0.56) | NPC1RAB9ARECQLKMT2AMAPT | |
| SCHEMBL11545573 | 0.89 | NPC1 (0.61) | NPC1RAB9ARECQLKMT2AMAPT | |
| SCHEMBL11545921 | 0.88 | NPC1 (0.68) | NPC1RAB9ARECQLKMT2AMAPT | |
| SCHEMBL11539115 | 0.85 | NPC1 (0.56) | NPC1RAB9ARECQLKMT2AMAPT | |
| SCHEMBL1340160 | 0.84 | NPC1 (0.74) | NPC1RAB9ARECQLKMT2AMAPT | |
| SCHEMBL907922 | 0.84 | ALDH1A1 (0.57) | NPC1RAB9ARECQLKMT2AMAPT | |
| SCHEMBL7335153 | 0.84 | NPC1 (0.54) | NPC1RAB9ARECQLKMT2AMAPT | |
| SCHEMBL9416503 | 0.84 | NPC1 (0.54) | NPC1RAB9ARECQLKMT2AMAPT | |
| SCHEMBL28436127 | 0.84 | NPC1 (0.54) | NPC1RAB9ARECQLKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339663-B1 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2338886-A2 | Naphthalene derivatives | Novartis AG (CH) | 2011-06-29 | — | — | EP | disclosed |
| US-7045533-B2 | Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout | NOVARTIS AG (CH) | 2006-05-16 | — | — | US | disclosed |
| CN-1224598-C | Naphthalene derivatives | NOVARTIS AG (CH) | 2005-10-26 | — | — | CN | disclosed |
| US-20040053890-A1 | Naphthalene derivatives | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
| CN-1476424-A | Naphthalene derivatives | ��˹��ŵ�� | 2004-02-18 | — | — | CN | disclosed |
| EP-1339663-A2 | NAPHTHALENE DERIVATIVES | Novartis AG (CH) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042248-A2 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053890-A1 | Naphthalene derivatives | CYP1A1, SULT1E1, CYP2F1 | NPC1 62/4885RAB9A 1106/4885RECQL 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.